185 related articles for article (PubMed ID: 34178677)
1. Immune Microenvironment and Genetics in Malignant Pleural Mesothelioma.
Wadowski B; Bueno R; De Rienzo A
Front Oncol; 2021; 11():684025. PubMed ID: 34178677
[TBL] [Abstract][Full Text] [Related]
2. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
3. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
Patil NS; Righi L; Koeppen H; Zou W; Izzo S; Grosso F; Libener R; Loiacono M; Monica V; Buttigliero C; Novello S; Hegde PS; Papotti M; Kowanetz M; Scagliotti GV
J Thorac Oncol; 2018 Jan; 13(1):124-133. PubMed ID: 29079455
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma.
Hsu PC; Miao J; Wang YC; Zhang WQ; Yang YL; Wang CW; Yang CT; Huang Z; You J; Xu Z; Jablons DM; You L
J Cell Mol Med; 2018 Jun; 22(6):3139-3148. PubMed ID: 29575535
[TBL] [Abstract][Full Text] [Related]
5. Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma.
Rovers S; Janssens A; Raskin J; Pauwels P; van Meerbeeck JP; Smits E; Marcq E
Biomedicines; 2022 Mar; 10(3):. PubMed ID: 35327475
[TBL] [Abstract][Full Text] [Related]
6. Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients.
Marcq E; Waele J; Audenaerde JV; Lion E; Santermans E; Hens N; Pauwels P; van Meerbeeck JP; Smits ELJ
Oncotarget; 2017 Oct; 8(52):89722-89735. PubMed ID: 29163783
[TBL] [Abstract][Full Text] [Related]
7. Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement.
Bronte G; Delmonte A; Burgio MA; Verlicchi A; Puccetti M; Bravaccini S; Cravero P; Tumedei MM; Diano D; Rossi G; Ulivi P; Martinelli G; Crinò L
Lung Cancer; 2020 Apr; 142():47-50. PubMed ID: 32088605
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications.
Tolani B; Acevedo LA; Hoang NT; He B
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29342862
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma.
Minnema-Luiting J; Vroman H; Aerts J; Cornelissen R
Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29601534
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients.
Fusco N; Vaira V; Righi I; Sajjadi E; Venetis K; Lopez G; Cattaneo M; Castellani M; Rosso L; Nosotti M; Clerici M; Ferrero S
Lung Cancer; 2020 Dec; 150():53-61. PubMed ID: 33065463
[TBL] [Abstract][Full Text] [Related]
11. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
Combaz-Lair C; Galateau-Sallé F; McLeer-Florin A; Le Stang N; David-Boudet L; Duruisseaux M; Ferretti GR; Brambilla E; Lebecque S; Lantuejoul S
Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma.
Marcq E; Siozopoulou V; De Waele J; van Audenaerde J; Zwaenepoel K; Santermans E; Hens N; Pauwels P; van Meerbeeck JP; Smits EL
Oncoimmunology; 2017; 6(1):e1261241. PubMed ID: 28197385
[TBL] [Abstract][Full Text] [Related]
13. Genomics and Functional Genomics of Malignant Pleural Mesothelioma.
Cakiroglu E; Senturk S
Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32882916
[TBL] [Abstract][Full Text] [Related]
14. The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma.
Thapa B; Salcedo A; Lin X; Walkiewicz M; Murone C; Ameratunga M; Asadi K; Deb S; Barnett SA; Knight S; Mitchell P; Watkins DN; Boutros PC; John T
J Thorac Oncol; 2017 May; 12(5):850-859. PubMed ID: 28257959
[TBL] [Abstract][Full Text] [Related]
15. [Systemic Treatment of Malignant Pleural Mesothelioma].
Nakano T
Gan To Kagaku Ryoho; 2017 Dec; 44(13):2041-2047. PubMed ID: 29361614
[TBL] [Abstract][Full Text] [Related]
16. Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.
Inaguma S; Lasota J; Wang Z; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Ikeda H; Schrump DS; Hassan R; Miettinen M
Hum Pathol; 2018 Jan; 71():1-7. PubMed ID: 28811252
[TBL] [Abstract][Full Text] [Related]
17. Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma.
Watanabe T; Okuda K; Murase T; Moriyama S; Haneda H; Kawano O; Yokota K; Sakane T; Oda R; Inagaki H; Nakanishi R
Oncotarget; 2018 Apr; 9(29):20769-20780. PubMed ID: 29755688
[TBL] [Abstract][Full Text] [Related]
18. Novel Therapeutic Targets and Immune Dysfunction in Malignant Pleural Mesothelioma.
Lapidot M; Saladi SV; Salgia R; Sattler M
Front Pharmacol; 2021; 12():806570. PubMed ID: 35069219
[TBL] [Abstract][Full Text] [Related]
19. Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma.
de Perrot M; Wu L; Cabanero M; Perentes JY; McKee TD; Donahoe L; Bradbury P; Kohno M; Chan ML; Murakami J; Keshavjee S; Tsao MS; Cho BCJ
J Thorac Cardiovasc Surg; 2020 May; 159(5):2082-2091.e1. PubMed ID: 31866087
[TBL] [Abstract][Full Text] [Related]
20. The Immune Microenvironment of Malignant Pleural Mesothelioma: A Literature Review.
Désage AL; Karpathiou G; Peoc'h M; Froudarakis ME
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34206956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
